W. Amon and P. J. Farrell, Reactivation of Epstein-Barr virus from latency, Rev Med Virol, vol.15, pp.149-156, 2005.

L. Mellemkjaer, M. S. Linet, G. Gridley, M. Frisch, H. Møller et al., Rheumatoid arthritis and cancer risk, Eur J Cancer Oxf Engl, vol.32, pp.1753-1757, 1990.

R. San-juan, P. Comoli, S. Caillard, B. Moulin, H. H. Hirsch et al., Epstein-Barr virus-related posttransplant lymphoproliferative disorder in solid organ transplant recipients, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.20, pp.109-118, 2014.

B. Gärtner and J. K. Preiksaitis, EBV viral load detection in clinical virology, J Clin Virol Off Publ Pan Am Soc Clin Virol, vol.48, pp.82-90, 2010.

R. San-juan, O. Manuel, H. H. Hirsch, M. Fernández-ruiz, F. López-medrano et al., Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Crosssectional Survey, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.21, pp.604-605, 2015.

N. Balandraud, S. Guis, J. B. Meynard, I. Auger, J. Roudier et al., Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis, Arthritis Rheum, vol.57, pp.762-767, 2007.

F. J. Hsu and M. Komarovskaya, CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells, J Immunother Hagerstown Md, vol.25, pp.455-468, 1997.

P. Emery, The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis, Expert Opin Investig Drugs, vol.12, pp.673-681, 2003.

J. M. Kremer, R. Westhovens, M. Leon, D. Giorgio, E. Alten et al., Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig, N Engl J Med, vol.349, pp.1907-1915, 2003.

M. C. Genovese, J. Becker, M. Schiff, M. Luggen, Y. Sherrer et al., Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition, N Engl J Med, vol.353, pp.1114-1123, 2005.

J. S. Smolen and R. N. Maini, Interleukin-6: a new therapeutic target, Arthritis Res Ther, vol.8, issue.2, p.5, 2006.

N. Nishimoto, Interleukin-6 in rheumatoid arthritis, Curr Opin Rheumatol, vol.18, pp.277-281, 2006.

R. N. Maini, P. C. Taylor, J. Szechinski, K. Pavelka, J. Bröll et al., Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum, vol.54, pp.2817-2829, 2006.

K. Paul-pletzer, Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today Barc Spain, vol.42, pp.559-576, 1998.

J. S. Smolen, A. Beaulieu, A. Rubbert-roth, C. Ramos-remus, J. Rovensky et al., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, Lancet Lond Engl, vol.371, pp.987-997, 2008.

C. P. Larsen, T. C. Pearson, A. B. Adams, P. Tso, N. Shirasugi et al., Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.5, pp.443-453, 2005.

N. Bassil, L. Rostaing, C. Mengelle, S. Kallab, L. Esposito et al., Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant, Exp Clin Transplant Off J Middle East Soc Organ Transplant, vol.12, pp.212-219, 2014.

C. Mourgues, C. Henquell, Z. Tatar, B. Pereira, C. Nourisson et al., Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis, Jt Bone Spine Rev Rhum, vol.83, pp.412-415, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01883187

M. Fujieda, K. Tsuruga, T. Sato, H. Kikuchi, W. Tamaki et al., Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab, Mod Rheumatol Jpn Rheum Assoc, pp.1-6, 2016.

F. C. Arnett, S. M. Edworthy, D. A. Bloch, D. J. Mcshane, J. F. Fries et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, vol.31, pp.315-324, 1988.

J. S. Smolen, F. C. Breedveld, G. Eberl, I. Jones, M. Leeming et al., Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity, Arthritis Rheum, vol.38, pp.38-43, 1995.

K. Liang and S. L. Zeger, Longitudinal Data Analysis Using Generalized Linear Models, Biometrika, vol.73, pp.13-22, 1986.

, The R Project for Statistical Computing, 2016.

J. Yan and J. Fine, Estimating equations for association structures, Stat Med, vol.23, pp.859-874, 2004.

E. Baecklund, J. Askling, R. Rosenquist, A. Ekbom, and L. Klareskog, Rheumatoid arthritis and malignant lymphomas, Curr Opin Rheumatol, vol.16, pp.254-261, 2004.

E. Baecklund, C. Backlin, A. Iliadou, F. Granath, A. Ekbom et al., Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis, Arthritis Rheum, vol.54, pp.3774-3781, 2006.

E. Baecklund, A. Iliadou, J. Askling, A. Ekbom, C. Backlin et al., Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis Rheum, vol.54, pp.692-701, 2006.

A. L. Smitten, T. A. Simon, M. C. Hochberg, and S. Suissa, A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis, Arthritis Res Ther, vol.10, p.45, 2008.

F. Baldanti, P. Grossi, M. Furione, L. Simoncini, A. Sarasini et al., High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders, J Clin Microbiol, vol.38, pp.613-619, 2000.

B. Gridelli, M. Spada, S. Riva, M. Colledan, A. Segalin et al., Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation, Transpl Int Off J Eur Soc Organ Transplant, vol.13, issue.1, pp.399-401, 2000.

X. Mariette, D. Cazals-hatem, J. Warszawki, F. Liote, N. Balandraud et al., Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France, Blood, vol.99, pp.3909-3915, 2002.

S. Ruf, K. Behnke-hall, B. Gruhn, J. Bauer, M. Horn et al., Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation, J Clin Virol Off Publ Pan Am Soc Clin Virol, vol.53, pp.186-194, 2012.

M. A. Lopez-olivo, J. H. Tayar, J. A. Martinez-lopez, E. N. Pollono, J. P. Cueto et al., Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis, JAMA, vol.308, pp.898-908, 2012.

X. Mariette, J. Gottenberg, P. Ravaud, and B. Combe, Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries, Rheumatol Oxf Engl, vol.50, pp.222-229, 2011.

J. A. Singh, G. A. Wells, R. Christensen, T. Ghogomu, E. Maxwell et al., Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, vol.008794, 2011.

M. E. Weinblatt, L. W. Moreland, R. Westhovens, R. B. Cohen, S. M. Kelly et al., Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program, J Rheumatol, vol.40, pp.787-797, 2013.

C. Lahaye, M. Soubrier, A. Mulliez, T. Bardin, A. Cantagrel et al., Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry, Rheumatol Oxf Engl, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01881520

G. L. Erre, G. Mameli, D. Cossu, B. Muzzeddu, C. Piras et al., Increased Epstein-Barr Virus DNA Load and Antibodies Against EBNA1 and EA in Sardinian Patients with Rheumatoid Arthritis, Viral Immunol, vol.28, pp.385-390, 2015.

J. Ogawa, M. Harigai, T. Akashi, K. Nagasaka, F. Suzuki et al., Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody, Ann Rheum Dis, vol.65, pp.1667-1669, 2006.

M. Harigai, T. Nanki, R. Koike, M. Tanaka, K. Watanabe-imai et al., Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan, Mod Rheumatol Jpn Rheum Assoc, pp.1-9, 2016.